Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.23), $0.09 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $7.03 million versus the consensus estimate of $6.7 million.

“Seres continues to advance our microbiome programs, and the Company is well resourced to reach important corporate milestones in 2020, including two late-stage clinical readouts: SER-287 Phase 2b study in mild-to-moderate ulcerative colitis and SER-109 Phase 3 study in recurrent C. difficile infection,” said Eric D. Shaff, President and Chief Executive Officer at Seres. “We are very pleased that our SER-109 ECOSPOR III study is now approaching target enrollment. SER-109 could provide patients with a meaningful new treatment option and also provide definitive clinical validation for our microbiome therapeutic approach. We are eagerly looking forward to top-line results from both of these important programs.”

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.